Nymox releases Immunogenicity results for NX-1207 BPH Program
NX-1207 is in late stage Phase 3 development in the US for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.